Generics

Dorzolamide and dorzolamide-timolol have a market value of approximately $150 million, according to IQVIA.

Butalbital, acetaminophen and caffeine tablets had a market value of roughly $40 million, according to IQVIA July 2020 data.

Mallinckrodt and its U.S. subsidiaries, including its specialty generics-focused and specialty brands-related subsidiaries, as well as some of its international subsidiaries, have filed Chapter 11 petitions.

Kuvan tablet and powder for oral solution had a market value of approximately $489 million for the 12 months ended June 30, 2020.

Tecfidera had a market value of approximately $3.8 billion for the 12-month period ending August, according to IQVIA.

Biosimilars could reach $80 billion in aggregate sales over the next five years, including $16 billion to $36 billion in 2024, according to the IQVIA Institute for Human Data Science's study.

Zydus Cadila has obtained the Food and Drug Administration’s OK for generic Tecfidera, and a tentative nod for generic Ibrance.

Dr. Reddy’s generic Kuvan tablets are available in a dosage strength of 100 mg in 120-count bottles.